The management of treatment-experienced HIV patients (including virologic failure and switches).
James CutrellTomasz JodlowskiRoger J BedimoPublished in: Therapeutic advances in infectious disease (2020)
Significant advances in the potency and tolerability of antiretroviral therapy (ART) have led to very high rates of virologic success for most who remain adherent to therapy. As a result, the life expectancy of people living with HIV (PLWH) has increased significantly. PLWH do, however, continue to experience a significantly higher risk of noninfectious comorbidities and chronic age-related complications, including cardiovascular disease and malignancies, which are now the biggest drivers of this excess morbidity and mortality. Therefore, in addition to virologic failure, the management of the treatment-experienced patient increasingly requires optimization of ART to enhance tolerability, avoid drug-drug interactions, and mitigate non-AIDS complications and comorbid conditions. This article will present principles of the management of virologic failure, poor immunologic recovery, and strategies for optimizing ART in the setting of virologic suppression.
Keyphrases
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv positive
- hiv infected patients
- hiv aids
- cardiovascular disease
- end stage renal disease
- ejection fraction
- open label
- chronic kidney disease
- risk factors
- newly diagnosed
- type diabetes
- randomized controlled trial
- peritoneal dialysis
- case report
- emergency department
- clinical trial
- metabolic syndrome
- cardiovascular events
- mesenchymal stem cells
- hepatitis c virus
- adverse drug